Global pharmaceutical company Allergan has announced that it has completed the acquisition of Kythera Biopharmaceuticals, Inc in a transaction valued at approximately $2.1 billion.
The acquisition adds the treatment Kybella (deoxycholic acid), which became the first FDA approved non-surgical injection for submental fullness in April of this year, to Allergan’s portfolio.
Brent Saunders, CEO and president of Allergan said, “The completion of the Kythera acquisition is an important moment for Allergan, adding highly differentiated products and development programmes that enhance our product offering to global customers and their patients.”
Kybella, which causes the destruction of fat cells, will join Allergan’s existing portfolio of medical aesthetic products, which includes Botox, Juvéderm XC, Juvéderm Voluma and Latisse.
Originally published here